154 related articles for article (PubMed ID: 24859798)
1. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.
Kogawa T; Doi A; Shimokawa M; Fouad TM; Osuga T; Tamura F; Mizushima T; Kimura T; Abe S; Ihara H; Kukitsu T; Sumiyoshi T; Yoshizaki N; Hirayama M; Sasaki T; Kawarada Y; Kitashiro S; Okushiba S; Kondo H; Tsuji Y
Target Oncol; 2015 Mar; 10(1):125-33. PubMed ID: 24859798
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: superior progression-free survival is restricted to patients with measurable tumors and objective tumor response--a retrospective study.
Yang YH; Lin JK; Chen WS; Lin TC; Yang SH; Jiang JK; Lan YT; Lin CC; Yen CC; Tzeng CH; Teng HW
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1927-36. PubMed ID: 24934725
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
[TBL] [Abstract][Full Text] [Related]
5. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
6. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.
Giuliani J; Indelli M; Marzola M; Raisi E; Frassoldati A
Tumori; 2012; 98(4):408-12. PubMed ID: 23052154
[TBL] [Abstract][Full Text] [Related]
7. First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A; Artale S; Sciallero S; Guglielmi A; Fornarini G; Andreotti IC; Mammoliti S; Comandini D; Caprioni F; Bennicelli E; Andretta V; Siena S; Sobrero A
Ann Oncol; 2008 Apr; 19(4):711-6. PubMed ID: 18073221
[TBL] [Abstract][Full Text] [Related]
8. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab in third-line therapy of patients with metastatic colorectal cancer: A single institution experience.
Pantelic A; Markovic M; Pavlovic M; Jancic S
J BUON; 2016; 21(1):70-9. PubMed ID: 27061533
[TBL] [Abstract][Full Text] [Related]
10. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
Ricotta R; Vanzulli A; Moroni M; Colnago B; Oriani M; Nichelatti M; Sarnataro C; Venturini F; Di Bella S; Maiolani M; Giganti MO; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2013 Mar; 12(1):45-53. PubMed ID: 23041354
[TBL] [Abstract][Full Text] [Related]
12. Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yu Y; Ying J; Zhang W; Li W; Sun Y; Yang L; Cui C; Zeng Y; Zhou A
Asia Pac J Clin Oncol; 2019 Jun; 15(3):128-135. PubMed ID: 30693649
[TBL] [Abstract][Full Text] [Related]
13. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
Bouchahda M; Boige V; Smith D; Karaboué A; Ducreux M; Hebbar M; Lepère C; Focan C; Guimbaud R; Innominato P; Awad S; Carvalho C; Tumolo S; Truant S; De Baere T; Castaing D; Rougier P; Morère JF; Taieb J; Adam R; Lévi F;
Eur J Cancer; 2016 Nov; 68():163-172. PubMed ID: 27768923
[TBL] [Abstract][Full Text] [Related]
14. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Vincenzi B; Galluzzo S; Santini D; Rocci L; Loupakis F; Correale P; Addeo R; Zoccoli A; Napolitano A; Graziano F; Ruzzo A; Falcone A; Francini G; Dicuonzo G; Tonini G
Ann Oncol; 2011 May; 22(5):1141-1146. PubMed ID: 21115601
[TBL] [Abstract][Full Text] [Related]
15. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
Douillard JY; Zemelka T; Fountzilas G; Barone C; Schlichting M; Heighway J; Eggleton SP; Srimuninnimit V
Clin Colorectal Cancer; 2014 Mar; 13(1):14-26.e1. PubMed ID: 24370353
[TBL] [Abstract][Full Text] [Related]
16. Skin rash during cetuximab treatment in advanced colorectal cancer: is age a clinical predictor?
Giuliani J; Marzola M
J Gastrointest Cancer; 2013 Jun; 44(2):241-5. PubMed ID: 23532731
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerling R; Kirchner T; Jung A; Folwaczny M; Yang D; Ning Y; Sebio A; Stremitzer S; Sunakawa Y; Matsusaka S; Yamauchi S; Loupakis F; Cremolini C; Falcone A; Lenz HJ
Mol Cancer Ther; 2015 Oct; 14(10):2374-81. PubMed ID: 26206335
[TBL] [Abstract][Full Text] [Related]
18. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).
Piessevaux H; Buyse M; De Roock W; Prenen H; Schlichting M; Van Cutsem E; Tejpar S
Ann Oncol; 2009 Aug; 20(8):1375-82. PubMed ID: 19465422
[TBL] [Abstract][Full Text] [Related]
19. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A; Caliolo C; Sponziello F; Nacci A; Quaranta A; Mazzoni E; Lutrino SE; Rizzo P; Calvani N; Orlando L; Schiavone P; Fedele P; D'Amico M; Chetrì MC; Cinefra M; Ferrara P; Cinieri S
Tumori; 2015; 101(5):524-8. PubMed ID: 26045117
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Bowles DW; Kochenderfer M; Cohn A; Sideris L; Nguyen N; Cline-Burkhardt V; Schnadig I; Choi M; Nabell L; Chaudhry A; Ruxer R; Ucar A; Hausman D; Walker L; Spira A; Jimeno A
Clin Colorectal Cancer; 2016 Dec; 15(4):337-344.e2. PubMed ID: 27118441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
